On February 7, the NIH team presented an in-depth overview of the Neuromod Prize and discussed the competition’s goal to accelerate the development of targeted neuromodulation therapies. The speakers included:
- Tyler Best, Neuromod Prize Lead, NIH
- Taylor Gilliland, Challenge Policy Advisor, NIH
Following the presentation, the team answered questions from attendees. Watch the session recording and read on for highlights from the virtual event. Also, see answers to frequently asked questions about the competition.
Advancing innovations through new collaborations
Tyler Best discussed the role of prize competitions in helping connect academic and industry partners to advance innovative technologies. In particular, the NIH has seen public and private programs help foster collaboration and innovation in previously undervalued areas. The field of neuromodulation is experiencing a breakthrough moment, and improved collaborations can help support novel approaches and bring more solutions to patients.
“There is promising early-stage research demonstrating the selective targeting and regulation of multiple autonomic functions of the peripheral nervous system. However, these novel methods have not left the lab. Treatments and therapies that can regulate multiple functions would be an innovative addition to the field that significantly moves the needle on what’s possible for patients.”—Tyler Best, Neuromod Prize Lead, NIH
Submitting a concept by April 28
Interested Phase 1 participants can submit concept papers describing their proposed therapeutic approaches, their plans for conducting proof-of-concept studies, their rationales for therapeutic use, and their expectations for clinical impact. Submissions are due by April 28, and participants can explore the resource hub as they develop their concept papers.
Receive updates about future virtual events and other competition news: Subscribe to the Neuromod Prize newsletter.